Maria Fuertes,Endika Martín-Encinas,Asier Selas et al.
Maria Fuertes et al.
Introduction: Among the different topoisomerases, essential enzymes that play an important role in DNA processes such as replication and transcription, type I enzymes are targets of particular clinical importance for anti...
Emanuele Fabbrizi,Francesco Fiorentino,Antonello Mai et al.
Emanuele Fabbrizi et al.
Introduction: Sirtuins have gained significant prominence in scientific research due to their involvement in a wide array of biological processes, including DNA repair, genome stability, transcription modulation, and sign...
Therapeutic applications of benzoxaborole compounds: a patent and literature analysis (2019-2024) [0.03%]
苯氧基硼化合物的治疗应用：专利和文献分析（2019-2024）
Simone Giovannuzzi,Alessio Nocentini,Claudiu T Supuran et al.
Simone Giovannuzzi et al.
Introduction: Benzoxaborole is a boron-based heterocyclic scaffold with remarkable potential in medicinal chemistry. Its unique chemical structure and compatibility with biological systems have enabled the development of ...
Medicinal chemistry perspective of ERK1/2 inhibitors in cancer treatment: an updated patent review (2019-present) [0.03%]
ERK1/2抑制剂抗癌专利盘点(2019-至今)——药物化学视角
Ankit Kumar Singh,Ajad Chauhan,Vineet Prajapati et al.
Ankit Kumar Singh et al.
Introduction: The mitogen-activated protein kinase (MAPK) pathway also known as the RAS/RAF/MEK/ERK pathway is a vital intracellular signaling cascade that regulates apoptosis, differentiation, proliferation, and signal t...
EOTP-2025-ST-0028.R1Insights and trends in development of TEAD-YAP/TAZ inhibitors: a review of PCT patents (2022 to June 2025) [0.03%]
TEAD-YAP/TAZ抑制剂开发的洞察与趋势：2022年6月至2025年PCT专利综述
Te Fan,Zhong Yu,Aiping Xiao et al.
Te Fan et al.
Introduction: The transcription enhancer associated domain (TEAD) family has been well documented for its roles in modulating cancer development, primarily through interactions with its two co-activators: yes-associated p...
An updated patent review of small molecule glucagon receptor antagonists (2020-2024) [0.03%]
2020-2024年小分子胰高血糖素受体拮抗剂专利分析
Chunyang Wang,Liyang Lyu,Dongyang Liu et al.
Chunyang Wang et al.
Introduction: The glucagon receptor (GCGR) plays a pivotal role in diabetes management. While small molecule GCGR antagonists (GCGRAs) offer several advantages, including glycemic control, oral bioavailability, and cost-e...
Bo-Wen Wan,Cheng-Shi Jiang,Chunlin Zhuang
Bo-Wen Wan
Introduction: Mixed-spectrum kinase structural domain-like protein (MLKL), which emerged as a pivotal regulator in biomedical research, plays a critical role in necroptotic pathways. Recent advancements have underscored t...
Topoisomerase II inhibitors in oncology: an updated patent review (2016-present) [0.03%]
抗癌拓扑异构酶II抑制剂的专利回顾（2016-至今）
Eleonora Turrini,Francesca Maffei,Andrea Milelli et al.
Eleonora Turrini et al.
Introduction: Topoisomerase (topo) II inhibitors continue to represent a promising approach in anticancer therapy, although their clinical application is hampered by drug resistance and dose limiting toxicities. ...
Toll-like receptor agonists as cancer therapeutics: a patent review (2014-2024) [0.03%]
toll-like受体激动剂作为抗癌药物的专利回顾（2014-2024）
Pankaj Kumar,Zahid Bashir Zargar,Kanwaljit Chopra et al.
Pankaj Kumar et al.
Introduction: Toll-like receptors (TLRs) play key role in cancer immunotherapy by harnessing the immune system's natural response to target and fight tumors. Among various TLRs, mainly TLR3, TLR4, TLR7, TLR8, and TLR9, ha...
Bruton's tyrosine kinase (BTK) inhibitors: an updated patent review (2019-2024) [0.03%]
布鲁顿酪氨酸激酶(BTK)抑制剂专利回顾(2019-2024)更新版
Ze-Xi Cui,Sheng-Xin Yao,Yue-Xi Zhang et al.
Ze-Xi Cui et al.
Introduction: Bruton's tyrosine kinase (BTK) is a critical regulator in the pathogenesis of B-cell malignancies, inflammatory diseases, and autoimmune diseases. In recent years, BTK inhibitors have been a hot topic in dru...